Alzheimer’S Disease Disease – Global Clinical Trials Review, H2 2019

GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H2, 2019" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's DiseaseReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Pfizer Inc

Johnson & Johnson

Eisai Co Ltd

F. Hoffmann-La Roche Ltd

Eli Lilly and Co

Novartis AG

AstraZeneca Plc

Allergan Plc

GlaxoSmithKline Plc

The Lundbeck Foundation

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Report Guidance 7

GlobalData Clinical Trials Report Coverage 8

Clinical Trials by Region 9

Clinical Trials and Average Enrollment by Country 10

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13

Top Five Countries Contributing to Clinical Trials in Europe 14

Top Countries Contributing to Clinical Trials in North America 15

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 16

Top Five Countries Contributing to Clinical Trials in Central and South America 17

Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 18

Clinical Trials by Phase in G7 Countries 20

Clinical Trials in G7 Countries by Trial Status 21

Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 23

Clinical Trials by Phase in E7 Countries 25

Clinical Trials in E7 Countries by Trial Status 26

Clinical Trials by Phase 28

In Progress Trials by Phase 29

Clinical Trials by Trial Status 30

Clinical Trials by End Point Status 32

Subjects Recruited Over a Period of Time 33

Clinical Trials by Sponsor Type 34

Prominent Sponsors 35

Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 37

Prominent Drugs 39

Latest Clinical Trials News on Alzheimer's Disease 40

Nov 26, 2019: New study by TauRx shows a minimum dose of Hydromethylthionine could slow cognitive decline and brain atrophy in mild-to-moderate Alzheimer's Disease 40

Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference 41

Nov 20, 2019: Cognition Therapeutics to give webcast presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019 41

Nov 20, 2019: New research demonstrates second direct link between inflammasome activation and Alzheimer's Disease 41

Nov 20, 2019: Tonix Pharmaceuticals completes pre-IND meeting with FDA for TNX-102 SL as a clinical candidate for alcohol use disorder 42

Nov 19, 2019: Oligomerix and Feinstein Institutes publish In Vivo Alzheimer’s Disease treatment data 42

Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia 43

Nov 12, 2019: Avanir Pharmaceuticals to continue clinical development of investigational AVP-786 for the treatment of agitation in patients with Alzheimer's Dementia 43

Nov 12, 2019: MGC Pharma receives first Australian Government Grant for CogniCann phase IIb clinical trial, progress towards LSE dual listing 43

Nov 11, 2019: ORYZON to present data on vafidemstat at Upcoming International Conferences 44

Nov 08, 2019: EIP Pharma reports mixed results from neflamapimod Alzheimer’s trial 44

Nov 07, 2019: EIP Pharma announces U.S. FDA grants Fast-Track Designation to Neflamapimod as a treatment for Dementia with Lewy Bodies (DLB) 44

Nov 07, 2019: Inflazome provides update on Inzomelid 45

Nov 07, 2019: Inflazome provides update on Somalix 45

Nov 06, 2019: Alzheon publication defines new path for 2nd generation anti-amyloid drugs for Alzheimer’s Disease, supporting launch of phase 3 study with ALZ-801 oral tablet 45

Nov 04, 2019: Alzheimer's drug Oligomannate gets conditional approval in China 46

Nov 04, 2019: AZTherapies to present at the 25th Annual BIO-EUROPE International Partnering Conference 47

Nov 04, 2019: Biogen to host investor webcasts from clinical trials on Alzheimer’s Disease (CTAD) Congress 47

Oct 30, 2019: Cyclo Therapeutics signs agreement with Worldwide Clinical Trials to conduct Alzheimer’s Disease clinical trial 47

Oct 29, 2019: Unique Alzheimer's Disease Tau vaccine shows great potential in pre-clinical studies 47

Oct 24, 2019: Cassava Sciences clinical results in Alzheimer's selected as late-breaking news at CTAD 2019 48

Oct 23, 2019: Biogen plans to seek FDA approval for Alzheimer’s drug 48

Oct 22, 2019: Oligomerix presents preclinical data on Lead Alzheimer's disease candidate at Neuroscience 2019 49

Oct 21, 2019: INmune Bio announces potentially strong link between obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting 49

Oct 17, 2019: ProMIS Neurosciences advances Alzheimers disease program targeting neurotoxic forms of tau 49

Oct 17, 2019: INmune Bio announces presentation of data related to its lead compound XPro1595 at the Society for Neuroscience's Annual Meeting 50

Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit 50

Oct 10, 2019: BioXcel Therapeutics provides update on its Schizophrenia drug candidate BXCL501 50

Oct 09, 2019: IntelGenx receives positive DSMB recommendation for Montelukast VersaFilm phase 2a trial 51

Oct 08, 2019: ProMIS Neurosciences identifies novel antibody candidates for multiple system atrophy 51

Oct 04, 2019: Oryzon reveals positive data from anti-aggression drug vafidemstat 52

Oct 03, 2019: ACADIA Pharmaceuticals announces late-breaking oral presentation of the phase 3 HARMONY study of pimavanserin in dementia-related psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting 52

Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients 53

Sep 30, 2019: Sovateltide (PMZ-1620), an Endothelin-B receptor agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics 53

Sep 30, 2019: Cognitive Improvement Demonstrated With Xanamem: Actinogen Medical 53

Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study 54

Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder 55

Sep 24, 2019: Gene therapy shows promise repairing brain tissue damaged by stroke 56

Sep 23, 2019: ORYZON presents new data on vafidemstat 57

Sep 20, 2019: AC Immune receives first milestone payment from Lilly in small molecule Tau Morphomer program 57

Sep 19, 2019: Tetra Therapeutics sees rapid patient recruitment and representative patient diversity in its PICASSO Phase 2 Alzheimer’s Disease Trial 58

Sep 17, 2019: Cassava Sciences to assess Alzheimer’s drug in Phase IIb trial 58

Sep 17, 2019: Theranexus announces inclusion of last subject in its phase IB trial of THN201 59

Sep 16, 2019: Biogen and Eisai discontinue Alzheimer’s trials of BACE inhibitor 59

Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome 60

Sep 10, 2019: Neurotrope Alzheimer’s Phase II trial fails to meet endpoints 61

Sep 10, 2019: Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference 61

Sep 09, 2019: Cassava Sciences reports positive phase 2a clinical results in Alzheimer's Patients 61

Sep 09, 2019: New preclinical research suggests Tetra Therapeutics BPN14770 protects against memory loss and neuronal atrophy in Alzheimers disease 62

Sep 09, 2019: Axon announces positive results from phase II ADAMANT trial for AADvac1 in Alzheimers Disease 63

Sep 04, 2019: Cognition Therapeutics to give webcast presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019 64

Clinical Trial Profile Snapshots 65

Appendix 1257

Abbreviations 1257

Definitions 1257

Research Methodology 1258

Secondary Research 1258

About GlobalData 1259

Contact Us 1259

Source 1260

List of Tables

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2019* 9

Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 12

Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 13

Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 14

Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2019* 15

Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 16

Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 17

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 18

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 20

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 23

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 25

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 26

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2019* 28

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 29

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2019* 30

Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2019* 32

Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 33

Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 34

Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 36

Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 37

Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 39

List of Figures

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2019* 9

Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 12

Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 13

Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 14

Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 15

Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 16

Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 17

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 18

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 20

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 23

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 25

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 26

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2019* 28

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 29

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2019* 30

Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2019* 32

Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 33

Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 34

Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 35

Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 37

Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 39

GlobalData Methodology 1258

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports